Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GUCY1A1 | Q02108 | 2/20 | 0.52 |
| ▸ | GUCY1B1 | Q02153 | 2/20 | 0.52 |
| ▸ | PDE5A | O76074 | 16/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27925580 | 0.91 | PDE5A (0.51) | GUCY1A1GUCY1B1PDE5A | |
| SCHEMBL27907473 | 0.91 | ADORA3 (0.56) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL27907477 | 0.82 | PDE5A (0.52) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL12468045 | 0.82 | GUCY1A1 (0.53) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL29859454 | 0.79 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL28808978 | 0.79 | GUCY1A1 (0.55) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL9914175 | 0.79 | PDE5A (0.55) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL173468 | 0.78 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL16945957 | 0.77 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 | |
| SCHEMBL12468047 | 0.77 | GUCY1A1 (0.54) | GUCY1A1GUCY1B1PDE5AADORA3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103097387-A | Ring-fused pyrimidines and triazines and use thereof for treating and/or preventing cardiovascular diseases | BAYER IP GMBH | 2013-05-08 | — | — | CN | disclosed |